Health Benefits of Resveratrol
DOI:
https://doi.org/10.37285/ijpsn.2009.2.1.3Abstract
Resveratrol a polyphenolic phytoalexin possesses a variety of bioactivities associated with health promotion. Resveratrol is readily absorbed along with the other human dietary sources like peanuts, peanut butter, grapes, and red wine. The polyphenolic structure of resveratrol confers antioxidant activity and may reduce oxidant-induced apoptosis and low-density lipoprotein (LDL) oxidation. The cardioprotective activity of resveratrol is associated with the inhibition of platelet aggregation and LDL oxidation and the promotion of artery vasorelaxation. As a chemopreventing agent, resveratrol has been shown to inhibit tumor initiation, promotion, and progression, as well as inhibit the growth of cancerous cells through increased apoptosis and/or cell cycle blockage. Inflammatory processes are associated with the pathogenesis of many chronic diseases including heart disease and diabetes. In addition, the estrogenic activity of resveratrol may help in the prevention of post-menopausal osteophoresis. This review reveals potential health benefits and discusses the current preclinical studies of resveratrol.
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
Keywords:
Resveratrol, pharmacokinetics, Antioxidant, Breast cancer
Downloads
Published
2009-05-31
How to Cite
1.
D. SK, P. S, G. UR. Health Benefits of Resveratrol. Scopus Indexed [Internet]. 2009 May 31 [cited 2024 May 19];2(1):407-12. Available from: http://www.ijpsnonline.com/index.php/ijpsn/article/view/273
Issue
Section
Review Articles
References
Aziz MH, Nihal M, Fu VX, Jarrard DF and Ahmad N. Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins. Molecular Cancer Therapeutic. 5(5): (2006).PMID 16731767.
Baldwin AS Jr. The NF-kB and IkB proteins: new discoveries and insights. Annu. Rev. Immunol. 14: 649–683 (1996).
Bani D, Masini E, Bello MG, Bigazzi M and Sacchi TB. Relaxin activates the L-arginine-nitric oxide pathway in human breast cancer cells. Cancer Res. 55: 5272–5275 (1995).
Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C and Dorken B. Constitutive nuclear factor-kB-RelA activation is required for proliferation and survival of Hodgkin’s disease tumor cells. J. Clin. Invest. 100: 2961–2969 (1997).
Barnes PJ and Karin M. Nuclear factor-kB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl, J. Med. 336: 1066–1071 (1997).
Basly JP, Marre-Fournier F, LeBail JC, Habrioux G and Chulia AJ. Estrogenic/ antiestrogenic and scavenging properties of (E)- and (Z)-Resveratrol. Life Sci .66: 769–777 (2000).
Bowers JL, Tyulmenkov VV, Jernigan SC and Klinge CM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology. 141(10): 3657-3667 (2000).
Brand K, Page S, Walli AK, Neumeier D and Baeuerle PA. Role of nuclear factor-kB in atherogenesis. Exp. Physiol. 82: 297–304 (1997).
El-Mowafy AM. Resveratrol activates guanylyl cyclase in coronary arterial smooth muscle: a novel signaling mechanism in support of coronary protection. Biochem. Biophys. Res. Commun. 291: 1218–1224 (2000).
Fremont L. Biological effects of Resveratrol. Life Science. 66: 663–673 (2000).
Garvina, Öllingerb and Dabrosin. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Letters. 231: 113-122 (2006).
Gehm BD, McAndrews JM, Chien P and Jameson JL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. National. Academy of Sciences. 94(25): 14138-14143 (1997).
Ghosh S, May MJ and Kopp EB. NF-kB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16: 225–260 (1998).
Goddard, Ian. Resveratrol Bio availability Analysis. Sci.life-expansion. Retrieved on 2007-06-18.
Gusman J, Malonne H and Atassi G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of Resveratrol. Carcinogenesis. 22: 1111–1117 (2001).
Jang M, Cai L, Slowing KV, et al. Cancer chemopreventive activity of Resveratrol, a natural product derived from grapes. Science. 275: 218–220 (1997).
Jobin C, Panja A, Hellerbrand C, Iimuro Y, Didonato J, Brenner DA and Sartor RB. Inhibition of proinflammatory molecule production by adenovirusmediated expression of a nuclear factor kB super-repressor in human intestinal epithelial cells. J. Immunol. 160: 410–418 (1998).
Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B and Scheidereit C. Molecular mechanisms of constitutive NF-kB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene. 18: 943–953 (1999).
Lemos C, Peters GJ, Jansen G, Martel F and Calhau C. Modulation of folate uptake in cultured human colon adenocarcinoma Caco-2 cells by dietary compounds. Eur J Nutr. 46(6):329-336 (2007).
Levi, Pasche, Lucchini, Ghidoni, Ferraroni and La Vecchia. Resveratrol and breast cancer risk. European Journal of Cancer Prevention. 14(2): 139–142 (2005).
Lu R. and Serrero G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J. Cell Physiol. 179: 297–304 (1999).
Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP and Ducharme MP Metabolism and disposition of Resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J. Pharmacol. Exp. Ther. 302 (1): 369-373 (2002).
Mayo MW, Wang CY, Cogswell PC, Rogers-Graham KS, Lowe SW, Der CJ and Baldwin AS. Jr. Requirement of NF-kB activation to suppress p53-independent apoptosis induced by oncogenic Rats. Science (Washington DC ). 278: 1812–1815 (1997).
Miagkov AV, Kovalenko DV, Brown CE, Didsbury JR, Cogswell JP, Stimpson SA, Baldwin AS and Makarov SS. NF-kB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc. Natl. Acad. Sci. USA. 95: 13859–13864 (1998).
Palamara AT, Nencioini L, Aquilano K et al. Inhibition of influenza A virus replication by Resveratrol. Journal of Infectious Diseases. 191(10): 1719–1729 (2005).
Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H and Néri C. Resveratrol rescues mutant polyglutamine cytotoxicity in C. elegans and mammalian neurons. Nature Genetics. 4: 349-50 (2005).
Philippe Marambaud et al. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. Journal of Biological Chemistry. 280(45):37377-82 (2005).
Reuther JY, Reuther GW, Cortez D, Pendergast AM and Baldwin AS. Jr. A requirement for NF-kB activation in Bcr-Abl-mediated transformation. Genes Dev. 12: 968–981 (1998).
Savouret JF and Quesne M. Resveratrol and cancer: a review. Biomed. Pharmacother. 56: 84–87 (2002).
Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM and Sonenshein GE. Aberrant nuclear factor-kB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 100: 2952–2960 (1997).
Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, Cho-Chung YS and Longo DL. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol. Cell. Biol. 18: 3509–3517 (1998).
Stahl S, Chun TY and Gray WG. Phytoestrogens act as estrogen agonists in an estrogen-responsive pituitary cell line. Toxicol. Appl. Pharmacol. 152: 41–48 (1998).
Tang HY, Shih A, Cao HJ, Davis FB, Davis PJ and Lin HY. Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells. 5(8): (2006). PMID 16928824.
Verma IM and Stevenson J. IkB kinase: beginning, not the end. Proc. Natl. Acad. Sci. USA. 94: 11758–11760 (1997).
Yang CS, Landau JM, Huang MT and Newmark HL. Inhibition of carcinogenesis by dietary polyphenolic compounds. Ann. Rev. Nutr. 21: 381–406 (2001).
Baldwin AS Jr. The NF-kB and IkB proteins: new discoveries and insights. Annu. Rev. Immunol. 14: 649–683 (1996).
Bani D, Masini E, Bello MG, Bigazzi M and Sacchi TB. Relaxin activates the L-arginine-nitric oxide pathway in human breast cancer cells. Cancer Res. 55: 5272–5275 (1995).
Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C and Dorken B. Constitutive nuclear factor-kB-RelA activation is required for proliferation and survival of Hodgkin’s disease tumor cells. J. Clin. Invest. 100: 2961–2969 (1997).
Barnes PJ and Karin M. Nuclear factor-kB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl, J. Med. 336: 1066–1071 (1997).
Basly JP, Marre-Fournier F, LeBail JC, Habrioux G and Chulia AJ. Estrogenic/ antiestrogenic and scavenging properties of (E)- and (Z)-Resveratrol. Life Sci .66: 769–777 (2000).
Bowers JL, Tyulmenkov VV, Jernigan SC and Klinge CM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology. 141(10): 3657-3667 (2000).
Brand K, Page S, Walli AK, Neumeier D and Baeuerle PA. Role of nuclear factor-kB in atherogenesis. Exp. Physiol. 82: 297–304 (1997).
El-Mowafy AM. Resveratrol activates guanylyl cyclase in coronary arterial smooth muscle: a novel signaling mechanism in support of coronary protection. Biochem. Biophys. Res. Commun. 291: 1218–1224 (2000).
Fremont L. Biological effects of Resveratrol. Life Science. 66: 663–673 (2000).
Garvina, Öllingerb and Dabrosin. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Letters. 231: 113-122 (2006).
Gehm BD, McAndrews JM, Chien P and Jameson JL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. National. Academy of Sciences. 94(25): 14138-14143 (1997).
Ghosh S, May MJ and Kopp EB. NF-kB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16: 225–260 (1998).
Goddard, Ian. Resveratrol Bio availability Analysis. Sci.life-expansion. Retrieved on 2007-06-18.
Gusman J, Malonne H and Atassi G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of Resveratrol. Carcinogenesis. 22: 1111–1117 (2001).
Jang M, Cai L, Slowing KV, et al. Cancer chemopreventive activity of Resveratrol, a natural product derived from grapes. Science. 275: 218–220 (1997).
Jobin C, Panja A, Hellerbrand C, Iimuro Y, Didonato J, Brenner DA and Sartor RB. Inhibition of proinflammatory molecule production by adenovirusmediated expression of a nuclear factor kB super-repressor in human intestinal epithelial cells. J. Immunol. 160: 410–418 (1998).
Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B and Scheidereit C. Molecular mechanisms of constitutive NF-kB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene. 18: 943–953 (1999).
Lemos C, Peters GJ, Jansen G, Martel F and Calhau C. Modulation of folate uptake in cultured human colon adenocarcinoma Caco-2 cells by dietary compounds. Eur J Nutr. 46(6):329-336 (2007).
Levi, Pasche, Lucchini, Ghidoni, Ferraroni and La Vecchia. Resveratrol and breast cancer risk. European Journal of Cancer Prevention. 14(2): 139–142 (2005).
Lu R. and Serrero G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J. Cell Physiol. 179: 297–304 (1999).
Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP and Ducharme MP Metabolism and disposition of Resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J. Pharmacol. Exp. Ther. 302 (1): 369-373 (2002).
Mayo MW, Wang CY, Cogswell PC, Rogers-Graham KS, Lowe SW, Der CJ and Baldwin AS. Jr. Requirement of NF-kB activation to suppress p53-independent apoptosis induced by oncogenic Rats. Science (Washington DC ). 278: 1812–1815 (1997).
Miagkov AV, Kovalenko DV, Brown CE, Didsbury JR, Cogswell JP, Stimpson SA, Baldwin AS and Makarov SS. NF-kB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc. Natl. Acad. Sci. USA. 95: 13859–13864 (1998).
Palamara AT, Nencioini L, Aquilano K et al. Inhibition of influenza A virus replication by Resveratrol. Journal of Infectious Diseases. 191(10): 1719–1729 (2005).
Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H and Néri C. Resveratrol rescues mutant polyglutamine cytotoxicity in C. elegans and mammalian neurons. Nature Genetics. 4: 349-50 (2005).
Philippe Marambaud et al. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. Journal of Biological Chemistry. 280(45):37377-82 (2005).
Reuther JY, Reuther GW, Cortez D, Pendergast AM and Baldwin AS. Jr. A requirement for NF-kB activation in Bcr-Abl-mediated transformation. Genes Dev. 12: 968–981 (1998).
Savouret JF and Quesne M. Resveratrol and cancer: a review. Biomed. Pharmacother. 56: 84–87 (2002).
Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM and Sonenshein GE. Aberrant nuclear factor-kB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 100: 2952–2960 (1997).
Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, Cho-Chung YS and Longo DL. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol. Cell. Biol. 18: 3509–3517 (1998).
Stahl S, Chun TY and Gray WG. Phytoestrogens act as estrogen agonists in an estrogen-responsive pituitary cell line. Toxicol. Appl. Pharmacol. 152: 41–48 (1998).
Tang HY, Shih A, Cao HJ, Davis FB, Davis PJ and Lin HY. Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells. 5(8): (2006). PMID 16928824.
Verma IM and Stevenson J. IkB kinase: beginning, not the end. Proc. Natl. Acad. Sci. USA. 94: 11758–11760 (1997).
Yang CS, Landau JM, Huang MT and Newmark HL. Inhibition of carcinogenesis by dietary polyphenolic compounds. Ann. Rev. Nutr. 21: 381–406 (2001).
